TissueCypher® Barrett's Esophagus Test Outperformed Standard of Care in Risk-Stratifying Patients with Barrett's Esophagus

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #AI--Study shows TissueCypher outperformed pathology review in predicting progression to high-grade d...

September 14, 2023
11:00 AM

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #AI--Study shows TissueCypher outperformed pathology review in predicting progression to high-grade dysplasia or esophageal cancer in Barrett's patients.

Copyright 2023, Business Wire.

News category

Other news in Friendswood

7
October
NewsNews
Friendswood
Former Friendswood Mustang Booster Club president sentenced to 10 years in prison for stealing more than $200K Continue reading →
5
October
NewsNews
Friendswood
DecisionDx®-Melanoma Outperforms Memorial Sloan Kettering Cancer Center (MSKCC) Nomogram in Predicting Sentinel Lymph Node Positivity in Patients with Cutaneous Melanoma Continue reading →
4
October
NewsNews
Friendswood
Astros Await Divisional Round Foe Continue reading →
3
October
NewsNews
Friendswood
Castle Biosciences Presents New Data at ASTRO 2023 Highlighting Risk-Stratification Performance of DecisionDx®-SCC in Patients with Cutaneous Squamous Cell Carcinoma Eligible for Adjuvant Radiation Therapy Continue reading →
2
October
NewsNews
Friendswood
Barbie truck with exclusive merch stopping at 2 Houston-area malls during Texas tour Continue reading →
2
October
NewsNews
Friendswood
Castle Biosciences Shares New Data Demonstrating Ability of TissueCypher® Test Results to Inform Clinical Decision-Making in Patients with Non-Dysplastic Barrett's Esophagus Continue reading →